Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Alexion Pharmaceuticals Inc. (ALXN) Message Board

Billionaire Steve Cohen\'s Point72 Asset Management Bets on Achillion

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 94
Posted On: 05/30/2015 8:45:46 PM
Posted By: riddock57
In a new filing (SC 13G) with the Securities and Exchange Commission (SEC), billionaire Steve Cohen's Point72 Asset Management, L.P. has disclosed a 5% (5,879,244 shares) stake in Achillion Pharmaceuticals, Inc. (ACHN) .

ACHN recently announced an agreement with Janssen Pharmaceuticals to develop and commercialize one or more of ACHN's lead hepatitis C virus (HCV) assets, including ACH-3102, ACH-3422, and sovaprevir. According to the company, the deal calls for up to $1.1 billion in potential development, regulatory and sales milestone payments and a separate equity investment.

ACHN, a biopharmaceutical company, focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.

More about Achillion Pharmaceuticals, Inc. (ACHN) at www.achillion.com

**

On Friday, Stonepine Capital, L.P. disclosed in an SEC filing (SC 13G) a 5.2% (1,500,000 shares) stake in Aegerion Pharmaceuticals, Inc. (AEGR) .

AEGR reported total net product sales of $59.4 million for the first quarter and expects to generate positive cash flow from operations for the full year 2015.

AEGR is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.

More about Aegerion Pharmaceuticals, Inc. (AEGR) at www.aegerion.com

**

After the closing bell on Friday, Enstar Group Ltd. (ESGR) said that Canada Pension Plan Investment Board, a professional investment management organization, has entered into an agreement to acquire approximately 1.9 million voting and non-voting ordinary shares of the company from private equity firm First Reserve.

The shares represent an approximately 9.9% stake in ESGR and the transaction is expected to be completed next week.

ESGR reported consolidated net earnings of $44.8 million (or $2.32 per fully diluted share) for the first quarter ended March 31, 2015.

ESGR and its operating subsidiaries acquire and manage diversified insurance businesses through a network of service companies in Bermuda, the United States, the United Kingdom, Continental Europe, Australia, and other international locations.

More about Enstar Group Ltd. (ESGR) at www.enstargroup.com

**

Crown Equity Holdings Inc. (CRWE) has updated its business plan ( http://crownequityholdings.com/extras/Business_Plan.pdf )

The company is currently developing its CRWE PR Network, which disseminates community, state, national and global news & information and is also the portal in promoting the company's services, such as its business directory, business-to-business global trading, real estate, press release and video distribution, discounted vouchers and advertising platforms.

CRWE's growing network of community targeted sites is expected to be a one-stop shop for the various needs of consumers.

The company's CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE PR Network. It will allow people to submit their listings for exposure to visitors searching for homes.

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer


(0)
(0)




Alexion Pharmaceuticals Inc. (ALXN) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us